{"id":754,"date":"2020-02-17T21:57:56","date_gmt":"2020-02-17T16:27:56","guid":{"rendered":"https:\/\/medicineplexus.com\/?p=754"},"modified":"2020-02-17T21:57:56","modified_gmt":"2020-02-17T16:27:56","slug":"drugs-used-in-psoriasis","status":"publish","type":"post","link":"https:\/\/medicineplexus.com\/drugs-used-in-psoriasis\/","title":{"rendered":"Drugs used in Psoriasis"},"content":{"rendered":"\n
Drugs used in Psoriasis<\/strong><\/p>\n\n\n\n Psoriasis-<\/strong> autoimmune<\/strong> disease <\/p>\n\n\n\n Topical corticosteroids<\/strong><\/p>\n\n\n\n Acitretin in Psoriasis<\/strong><\/p>\n\n\n\n Mechanism of Action<\/strong><\/p>\n\n\n\n Indications<\/p>\n\n\n\n \u2022 severe extensive psoriasis that is resistant to other forms of therapy,<\/p>\n\n\n\n \u2022 palmoplantar pustular psoriasis<\/p>\n\n\n\n Acitretin is not indicated in the treatment of psoriatic arthritis.<\/p>\n\n\n\n Calcipotriene and Calcipotriol<\/strong><\/p>\n\n\n\n Tazarotene<\/strong><\/p>\n\n\n\n Salicylic acid<\/strong><\/p>\n\n\n\n Coal tar<\/strong><\/p>\n\n\n\n Calcineurin inhibitors<\/strong> \u2014<\/p>\n\n\n\n Topical tacrolimus 0.1%<\/strong> and pimecrolimus 1%<\/strong> are effective in the treatment of psoriasis in sensitive areas . Facial and intertriginous areas may be well suited to these treatments, which can allow patients to avoid or minimize chronic topical corticosteroid use<\/p>\n\n\n\n PHOTOTHERAPY<\/strong><\/p>\n\n\n\n <\/strong>Induces apoptosis & enhanced transcription and expression of IL-10 in keratinocytes<\/p>\n\n\n\n s\/e – redness, itching and dry skin<\/p>\n\n\n\n Narrow band UVB therapy(311-313 nm)<\/strong> -More effective than broadband UVB treatment<\/p>\n\n\n\n Usually administered 2 to 3 times a week until the skin improves, then maintenance may require only weekly sessions<\/p>\n\n\n\n Narrow band UVB therapy may cause more severe and longer lasting burns<\/p>\n\n\n\n PUVA <\/strong>(2 to 3 sessions a week) \u2013<\/p>\n\n\n\n Psoralen<\/strong> sensitizes the skin to UV rays \u00e0 More aggressive therapy<\/p>\n\n\n\n s\/e – headache, burning and itching, wrinkled skin, freckles & skin cancer<\/p>\n\n\n\n Tumor Necrosis Factor Inhibitors<\/strong><\/p>\n\n\n\n Because certolizumab pegol lacks the Fc portion, it is not able to activate complement-mediated cytotoxicity.<\/p>\n\n\n\n METHOTREXATE<\/strong><\/p>\n\n\n\n DHFRase inhibitor \u2013 weekly administration<\/p>\n\n\n\n s\/e – Myelosuppression, mucositis Hepatotoxicity, pulmonary fibrosis, Nephrotoxicity, neurotoxic <\/p>\n\n\n\n IL-12\/23 Inhibitors- Ustekinumab<\/strong><\/p>\n\n\n\n IL-17 Inhibitors- <\/strong>Secukinumab (jan 2015<\/strong>), IXEKIZUMAB (march 2016)<\/p>\n\n\n\n barrier dysfunction<\/p>\n\n\n\n PDE4 Inhibitors- Apremilast<\/strong><\/p>\n\n\n\n Jak Inhibitors<\/strong><\/p>\n\n\n\n IL-4 Inhibitors<\/strong><\/p>\n\n\n\n of IL-4R that inhibits both IL-4 and IL-13 signaling as they each exert their action through binding an IL-4R\u03b1\/IL-13R\u03b11 receptor complex<\/p>\n\n\n\n Drugs used in Psoriasis Psoriasis- autoimmune disease five main types of psoriasis: plaque, guttate, inverse, pustular, and erythrodermic. Plaque psoriasis, also known as psoriasis vulgaris, makes up about 90% of cases. Psoriasis is characterized by an abnormally excessive and rapid growth of the epidermal layer of the skin. chronic, non-contagious disease of the skin, in[…]\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"","_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"","footnotes":""},"categories":[3],"tags":[],"_links":{"self":[{"href":"https:\/\/medicineplexus.com\/wp-json\/wp\/v2\/posts\/754"}],"collection":[{"href":"https:\/\/medicineplexus.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicineplexus.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicineplexus.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/medicineplexus.com\/wp-json\/wp\/v2\/comments?post=754"}],"version-history":[{"count":0,"href":"https:\/\/medicineplexus.com\/wp-json\/wp\/v2\/posts\/754\/revisions"}],"wp:attachment":[{"href":"https:\/\/medicineplexus.com\/wp-json\/wp\/v2\/media?parent=754"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicineplexus.com\/wp-json\/wp\/v2\/categories?post=754"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicineplexus.com\/wp-json\/wp\/v2\/tags?post=754"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Patients being considered for treatment with biologics should have severe disease defined by a total psoriasis area and severity index (PASI) score of 10 or more (20 for infliximab)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n IL-17 A RECEPTOR INHIBITOR<\/u><\/strong> – BRODALUMAB \u2013 <\/strong>Feb 2017 FDA approved. Black box warning-<\/u><\/strong> <\/strong>Suicidal ideation and behavior, including completed suicides, have occurred in patients treated with brodalumab. Prior to prescribing brodalumab, weigh the potential risks and benefits in patients with a history of depression and\/or suicidal ideation or behavior. <\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n IL-23 INHIBITOR<\/u><\/strong> – GUSELKUMAB (<\/strong>July 2017)<\/strong>IL-23 INHIBITOR<\/u><\/strong> – Tildrakizumab (<\/strong>March 2018)<\/strong>for the treatment of moderate to severe plaque psoriasisselectively blocks interleukin (IL)-23.<\/em><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n Certolizumab pegol \u2014<\/u><\/strong>TNF-alpha inhibitorIn 2018, the FDA approved the drug for the treatment of adults with moderate to severe psoriasis who are candidates for systemic therapy or phototherapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n